Concord Biotech Shares Rise After US FDA Approves Mycophenolate Mofetil

Concord Biotech's stock rose following US FDA approval of its Mycophenolate Mofetil product. Business Standard reported the development. The approval allows the company to market the immunosuppressive drug. Mycophenolate Mofetil is used to prevent organ transplant rejection. The clearance marks a regulatory milestone for Concord Biotech. It may boost the firm's revenue prospects. Analysts view the approval as validation of the company's pipeline. The market will watch subsequent sales performance.